• Mechanism Of Action
  • Mechanism Of Action

TRODELVY 200mg

Mechanism Of Action

TRODELVY: the first and only approved TROP-2-directed ADC1

TRODELVY is a TROP-2-directed ADC that delivers SN-38 to both cancer cells and the tumour microenvironment via 2 cytotoxic mechanisms2,3

approved TROP-2-directed ADC

The proposed mechanism of action is based on preclinical data, which may not correlate with clinical outcomes.

Adapted from Rugo HS, et al. 2020.

ABBREVIATIONS:

ADC, antibody-drug conjugate; TOPO I, topoisomerase 1; TROP-2, trophoblast cell surface antigen 2.

REFERENCES:

  1. Bardia A, et al. Presented at the Virtual 2020 ESMO Congress.
  2. Rugo HS, et al. Future Oncol. 2020;16(12):705–715.
  3. TRODELVY (sacituzumab govitecan) Summary of Product Characteristics, February 2023.